DFTX
Definium Therapeutics, Inc.
+0.94 (+2.48%)38.79USD704K成交股數5.2B市值–本益比(近四季)1117.5股價營收比–營收年增(近四季)2026-11-05下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 6 · 3.3M · 5 |
| 其中 10b5-1 計畫賣出 | 6 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 4.1M |
| 近 180 天 淨額 | −4.1M |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 | 09-14 | Sullivan Mark | Chief Legal Officer | A 獲配股票 | 125K | – | – | 508K | SEC |
| 2026-09-14 | 09-14 | Roberts Brandi | Chief Financial Officer | A 獲配股票 | 125K | – | – | 398K | SEC |
| 2026-09-14 | 09-14 | Barrow Robert | Chief Executive Officer | A 獲配股票 | 750K | – | – | 2.2M | SEC |
| 2026-09-14 | 09-14 | Karlin Daniel | Chief Medical Officer | A 獲配股票 | 200K | – | – | 804K | SEC |
| 2026-09-14 | 09-14 | Wiley Matthew T. | Chief Commercial Officer | A 獲配股票 | 125K | – | – | 362K | SEC |
| 2026-09-03 | 09-04 | Barrow Robert | Chief Executive Officer | S 公開市場賣出(10b5-1) | 19.0K | 37.94 | 722K | 1.5M | SEC |
| 2026-09-02 | 09-04 | Barrow Robert | Chief Executive Officer | A 獲配股票 | 40.0K | – | – | 1.5M | SEC |
| 2026-08-12 | 08-12 | Karlin Daniel | Chief Medical Officer | A 獲配股票 | 100K | – | – | 603K | SEC |
| 2026-08-12 | 08-12 | Barrow Robert | Chief Executive Officer | A 獲配股票 | 375K | – | – | 1.5M | SEC |
| 2026-08-12 | 08-12 | Roberts Brandi | Chief Financial Officer | A 獲配股票 | 62.5K | – | – | 272K | SEC |
| 2026-08-12 | 08-12 | Sullivan Mark | Chief Legal Officer | A 獲配股票 | 62.5K | – | – | 383K | SEC |
| 2026-08-12 | 08-12 | Wiley Matthew T. | Chief Commercial Officer | A 獲配股票 | 62.5K | – | – | 237K | SEC |
| 2026-06-25 | 06-26 | Wiley Matthew T. | Chief Commercial Officer | S 公開市場賣出(10b5-1) | 2.9K | 45.03 | 129K | 175K | SEC |
| 2026-06-25 | 06-26 | Barrow Robert | Chief Executive Officer | S 公開市場賣出(10b5-1) | 29.2K | 45.03 | 1.3M | 1.1M | SEC |
| 2026-06-25 | 06-26 | Roberts Brandi | Chief Financial Officer | S 公開市場賣出(10b5-1) | 3.0K | 45.03 | 136K | 209K | SEC |
| 2026-06-25 | 06-26 | Karlin Daniel | Chief Medical Officer | S 公開市場賣出(10b5-1) | 10.0K | 45.03 | 452K | 503K | SEC |
| 2026-06-25 | 06-26 | Sullivan Mark | Chief Legal Officer | S 公開市場賣出(10b5-1) | 13.0K | 45.03 | 586K | 321K | SEC |
| 2026-06-22 | 06-22 | Sullivan Mark | Chief Legal Officer | A 獲配股票 | 62.5K | – | – | 334K | SEC |
| 2026-06-22 | 06-22 | Karlin Daniel | Chief Medical Officer | A 獲配股票 | 100K | – | – | 513K | SEC |
| 2026-06-22 | 06-22 | Roberts Brandi | Chief Financial Officer | A 獲配股票 | 62.5K | – | – | 213K | SEC |
| 2026-06-22 | 06-22 | Wiley Matthew T. | Chief Commercial Officer | A 獲配股票 | 62.5K | – | – | 178K | SEC |
| 2026-06-22 | 06-22 | Barrow Robert | Chief Executive Officer | A 獲配股票 | 375K | – | – | 1.1M | SEC |
| 2026-06-11 | 06-15 | Bruhn Suzanne Louise | Director | A 獲配股票 | 4.7K | – | – | 24.3K | SEC |
| 2026-06-11 | 06-15 | Adsett Roger | Director | A 獲配股票 | 3.6K | – | – | 3.6K | SEC |
| 2026-06-11 | 06-15 | Krebs Andreas | Director | A 獲配股票 | 4.7K | – | – | 19.8K | SEC |
| 2026-06-11 | 06-15 | Vallone Carol A | Director | A 獲配股票 | 4.7K | – | – | 21.2K | SEC |
| 2026-06-11 | 06-15 | GRYSKA DAVID W | Director | A 獲配股票 | 4.7K | – | – | 19.9K | SEC |
| 2026-06-11 | 06-15 | CRYSTAL ROGER | Director | A 獲配股票 | 4.7K | – | – | 24.3K | SEC |
| 2026-03-25 | 03-26 | Barrow Robert | Chief Executive Officer | S 公開市場賣出(10b5-1) | 24.4K | 18.47 | 451K | 752K | SEC |
| 2026-03-25 | 03-26 | Sullivan Mark | Chief Legal Officer | S 公開市場賣出(10b5-1) | 10.7K | 18.47 | 198K | 271K | SEC |
| 2026-03-25 | 03-26 | Karlin Daniel | Chief Medical Officer | S 公開市場賣出(10b5-1) | 8.0K | 18.47 | 148K | 413K | SEC |
| 2026-02-03 | 02-05 | Barrow Robert | Chief Executive Officer | A 獲配股票 | 320K | – | – | 1.1M | SEC |
| 2026-02-03 | 02-05 | Karlin Daniel | Chief Medical Officer | A 獲配股票 | 150K | – | – | 575K | SEC |
| 2026-02-03 | 02-05 | Sullivan Mark | Chief Legal Officer | A 獲配股票 | 125K | – | – | 408K | SEC |
| 2026-02-03 | 02-05 | Roberts Brandi | Chief Financial Officer | A 獲配股票 | 150K | – | – | 150K | SEC |
| 2026-02-03 | 02-05 | Wiley Matthew T. | Chief Commercial Officer | A 獲配股票 | 115K | – | – | 115K | SEC |
| 2025-12-26 | 12-29 | Sullivan Mark | Chief Legal Officer | S 公開市場賣出(10b5-1) | 11.3K | 13.15 | 148K | 283K | SEC |
| 2025-12-26 | 12-29 | Barrow Robert | Chief Executive Officer | S 公開市場賣出(10b5-1) | 25.8K | 13.15 | 339K | 778K | SEC |
| 2025-12-26 | 12-29 | Karlin Daniel | Chief Medical Officer | S 公開市場賣出(10b5-1) | 5.6K | 13.15 | 74K | 425K | SEC |
| 2025-09-25 | 09-26 | Karlin Daniel | Chief Medical Officer | S 公開市場賣出(10b5-1) | 7.7K | 9.77 | 75K | 431K | SEC |
| 2025-09-25 | 09-26 | Barrow Robert | Chief Executive Officer | S 公開市場賣出(10b5-1) | 25.8K | 9.77 | 252K | 804K | SEC |
| 2025-09-25 | 09-26 | Sullivan Mark | Chief Legal Officer | S 公開市場賣出(10b5-1) | 11.3K | 9.77 | 110K | 294K | SEC |
| 2025-06-25 | 06-26 | Barrow Robert | Chief Executive Officer | S 公開市場賣出(10b5-1) | 26.5K | 6.80 | 180K | 830K | SEC |
| 2025-06-25 | 06-26 | Karlin Daniel | Chief Medical Officer | S 公開市場賣出(10b5-1) | 7.8K | 6.80 | 53K | 438K | SEC |
| 2025-06-25 | 06-26 | Sullivan Mark | Chief Legal Officer | S 公開市場賣出(10b5-1) | 11.5K | 6.80 | 78K | 305K | SEC |
| 2025-03-25 | 03-26 | Liao Carrie | Chief Accounting Officer | S 公開市場賣出(10b5-1) | 2.3K | 6.74 | 16K | 145K | SEC |
| 2025-03-25 | 03-26 | Sullivan Mark | Chief Legal Officer | S 公開市場賣出(10b5-1) | 6.6K | 6.74 | 44K | 317K | SEC |
| 2025-03-25 | 03-26 | Karlin Daniel | Chief Medical Officer | S 公開市場賣出(10b5-1) | 6.8K | 6.74 | 46K | 446K | SEC |
| 2025-03-25 | 03-26 | Barrow Robert | Chief Executive Officer | S 公開市場賣出(10b5-1) | 21.2K | 6.74 | 143K | 857K | SEC |
| 2025-03-12 | 03-13 | Liao Carrie | Chief Accounting Officer | A 獲配股票 | 50.0K | – | – | 142K | SEC |
| 2025-03-12 | 03-13 | Sullivan Mark | Chief Legal Officer | A 獲配股票 | 150K | – | – | 323K | SEC |
| 2025-03-12 | 03-13 | Karlin Daniel | Chief Medical Officer | A 獲配股票 | 115K | – | – | 453K | SEC |
| 2025-03-12 | 03-13 | Barrow Robert | Chief Executive Officer | A 獲配股票 | 350K | – | – | 878K | SEC |
| 2024-12-26 | 12-27 | Sullivan Mark | Chief Legal Officer | S 公開市場賣出(10b5-1) | 4.5K | 7.43 | 34K | 173K | SEC |
| 2024-12-26 | 12-27 | Karlin Dan | Chief Medical Officer | S 公開市場賣出(10b5-1) | 6.6K | 7.43 | 49K | 338K | SEC |
| 2024-12-26 | 12-27 | Liao Carrie | Chief Accounting Officer | S 公開市場賣出(10b5-1) | 2.3K | 7.43 | 17K | 97.3K | SEC |
| 2024-12-26 | 12-27 | Barrow Robert | Chief Executive Officer | S 公開市場賣出(10b5-1) | 19.1K | 7.43 | 142K | 527K | SEC |
| 2024-12-05 | 12-05 | GRYSKA DAVID W | Director | P 公開市場買進 | 2.5K | 7.17 | 18K | 19.9K | SEC |
| 2024-09-25 | 09-25 | Sullivan Mark | Chief Legal Officer | S 公開市場賣出(10b5-1) | 4.4K | 5.98 | 26K | 178K | SEC |
| 2024-09-25 | 09-25 | Karlin Dan | Chief Medical Officer | S 公開市場賣出(10b5-1) | 6.9K | 5.98 | 41K | 345K | SEC |
| 2024-09-25 | 09-25 | Barrow Robert | Chief Executive Officer | S 公開市場賣出(10b5-1) | 19.8K | 5.98 | 118K | 546K | SEC |
| 2024-09-25 | 09-25 | Liao Carrie | Chief Accounting Officer | S 公開市場賣出(10b5-1) | 2.4K | 5.98 | 14K | 99.5K | SEC |
| 2024-08-23 | 08-26 | GRYSKA DAVID W | Director | P 公開市場買進 | 3.5K | 5.98 | 21K | 17.4K | SEC |
| 2024-08-21 | 08-22 | Halperin Wernli Miri | Executive President | M 選擇權執行 | 50.0K | 3.70 | 185K | 235K | SEC |
| 2024-08-21 | 08-22 | Halperin Wernli Miri | Executive President | F 繳稅扣股 | 32.6K | 6.17 | 201K | 202K | SEC |
| 2024-08-20 | 08-20 | Barrow Robert | Chief Executive Officer | P 公開市場買進 | 500 | 6.12 | 3K | 566K | SEC |
| 2024-08-19 | 08-20 | Barrow Robert | Chief Executive Officer | P 公開市場買進 | 500 | 6.31 | 3K | 565K | SEC |
| 2024-06-25 | 06-25 | Barrow Robert | Chief Executive Officer | S 公開市場賣出(10b5-1) | 15.7K | 7.22 | 113K | 565K | SEC |
| 2024-06-25 | 06-25 | Karlin Dan | Chief Medical Officer | S 公開市場賣出(10b5-1) | 6.9K | 7.22 | 50K | 352K | SEC |
| 2024-06-25 | 06-25 | Sullivan Mark | Chief Legal Officer | S 公開市場賣出(10b5-1) | 17.9K | 7.22 | 129K | 182K | SEC |
| 2024-03-25 | 03-26 | Barrow Robert | Chief Executive Officer | S 公開市場賣出(10b5-1) | 16.5K | 9.50 | 157K | 580K | SEC |
| 2024-03-25 | 03-26 | Karlin Dan | Chief Medical Officer | S 公開市場賣出(10b5-1) | 6.6K | 9.50 | 62K | 358K | SEC |
| 2024-03-25 | 03-26 | Greenway Schond L. | Chief Financial Officer | F 繳稅扣股 | 5.6K | 9.78 | 54K | 211K | SEC |
| 2023-12-26 | 12-26 | Greenway Schond L. | Chief Financial Officer | S 公開市場賣出 | 5.7K | 3.63 | 21K | 217K | SEC |
| 2023-12-26 | 12-26 | Barrow Robert | Chief Executive Officer | S 公開市場賣出 | 13.2K | 3.63 | 48K | 597K | SEC |
| 2023-12-26 | 12-26 | Karlin Dan | Chief Medical Officer | S 公開市場賣出 | 6.8K | 3.63 | 25K | 365K | SEC |
| 2023-09-25 | 09-25 | Greenway Schond L. | Chief Financial Officer | S 公開市場賣出 | 1.9K | 3.57 | 7K | 226K | SEC |
| 2023-09-25 | 09-25 | Greenway Schond L. | Chief Financial Officer | S 公開市場賣出 | 3.9K | 3.58 | 14K | 222K | SEC |
| 2023-09-25 | 09-25 | Karlin Dan | Chief Medical Officer | S 公開市場賣出 | 3.7K | 3.57 | 13K | 375K | SEC |
| 2023-09-25 | 09-25 | Karlin Dan | Chief Medical Officer | S 公開市場賣出 | 3.2K | 3.58 | 12K | 372K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| BlackRock, Inc. | 11.2M | 528M | 新進 | 新進 |
| Avoro Capital Advisors LLC | 7.2M | 338M | 新進 | 新進 |
| Driehaus Capital Management LLC | 6.8M | 322M | 新進 | 新進 |
| Jupiter Topco LLC | 5.6M | 264M | 新進 | 新進 |
| Capital World Investors | 5.4M | 252M | 新進 | 新進 |
| FMR LLC | 4.8M | 224M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 3.6M | 171M | 新進 | 新進 |
| STATE STREET CORP | 3.1M | 144M | 新進 | 新進 |
| Capital International Investors | 3.0M | 139M | 新進 | 新進 |
| Octagon Capital Advisors LP | 3.0M | 139M | 新進 | 新進 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.9M | 139M | 新進 | 新進 |
| Deep Track Capital, LP | 2.8M | 129M | 新進 | 新進 |
| Commodore Capital LP | 2.0M | 94.1M | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 1.8M | 84.7M | 新進 | 新進 |
| 城堡 CITADEL ADVISORS LLC | 1.7M | 79.4M | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.6M | 77.5M | 新進 | 新進 |
| RA CAPITAL MANAGEMENT, L.P. | 1.5M | 70.6M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.5M | 69.9M | 新進 | 新進 |
| Siren, L.L.C. | 1.4M | 66.8M | 新進 | 新進 |
| MARSHALL WACE, LLP | 1.3M | 61.1M | 新進 | 新進 |
| NORTHERN TRUST CORP | 1.2M | 55.0M | 新進 | 新進 |
| AMERIPRISE FINANCIAL INC | 1.1M | 54.0M | 新進 | 新進 |
| Nuveen, LLC | 1.1M | 52.0M | 新進 | 新進 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.1M | 51.0M | 新進 | 新進 |
| Woodline Partners LP | 1.0M | 47.2M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 360 +115 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 360 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 115M · 85.4% |
| 合計季末市值 | 5.1B |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 9.8M |
|---|---|
| 與上期比 | +9.7% |
| 佔流通股數 | 7.32% |
| 日均成交量 | 1.7M |
| 回補天數 | 5.6 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 9.8M | +9.7% | 7.32% | 1.7M | 5.6 |
| 2026-08-14 | 9.0M | -16.5% | 6.68% | 2.7M | 3.4 |
| 2026-07-31 | 10.7M | +0.9% | 7.99% | 1.6M | 6.6 |
| 2026-07-15 | 10.6M | -26.7% | 7.92% | 2.3M | 4.7 |
| 2026-06-30 | 14.5M | +36.5% | 10.80% | 7.1M | 2.1 |
| 2026-06-15 | 10.6M | +12.8% | 7.92% | 2.4M | 4.4 |
| 2026-05-29 | 9.4M | +1.9% | 7.02% | 1.8M | 5.2 |
| 2026-05-15 | 9.2M | -1.1% | 6.88% | 1.4M | 6.6 |
| 2026-04-30 | 9.4M | -4.7% | 6.96% | 2.3M | 4.0 |
| 2026-04-15 | 9.8M | -35.1% | 7.31% | 1.7M | 5.9 |
| 2026-03-31 | 15.1M | +0.8% | 11.26% | 1.7M | 8.9 |
| 2026-03-13 | 15.0M | -22.4% | 11.17% | 1.8M | 8.3 |
| 2026-02-27 | 19.3M | -0.9% | 14.40% | 1.2M | 15.9 |
| 2026-02-13 | 19.5M | +10.4% | 14.52% | 1.4M | 13.5 |
| 2026-01-30 | 17.7M | +5.0% | 13.15% | 2.2M | 7.9 |
| 2026-01-15 | 16.8M | +11.8% | 12.53% | 2.3M | 7.3 |